You have read all your free articles, to continue reading subscribe to read the rest of this content.
Swedish Orphan Biovitrum has announced that it has decided to initiate two clinical programs with Kineret (anakinra) in North America, with the aim of evaluating two new potential indications for Kineret where a significant need for alternative treatment options exists: acute gout and Still's diseaAlready a subscriber Login You have read…
InDex Pharmaceuticals Holding has announced that the first patient has been enrolled in the phase III study CONCLUDE. The study will evaluate the efficacy and safety of the TLR9 agonist cobitolimod as a novel treatment for patients with moderate to severe left-sided ulcerative colitis. "Given coAlready a subscriber Login You…
The first patient has been dosed in an investigator-initiated phase II trial of bemcentinib, a selective, potent and orally bio-available AXL inhibitor, in patients with high-risk myelodysplastic syndrome (MDS) who have failed first-line treatment with hypomethylating agents. The trial (BGBIL009 Already a subscriber Login You have read all your free…
Pilloxa has announced the start of a single-armed and multicenter observational clinical trial in which their digital patient-centric adherence solution will be tested in patients with cardiovascular disease, namely newly diagnosed patients with atrial fibrillation. The study, ASTORIA, to be condAlready a subscriber Login You have read all your free…
